



**MINUTES OF THE FRED HUTCHINSON CANCER CENTER
INSTITUTIONAL BIOSAFETY COMMITTEE**

December 18, 2025 Special IBC Meeting, 2:00 pm, MS Teams

ATTENDANCE

MEMBERS

Present	Absent	
<input checked="" type="checkbox"/>	<input type="checkbox"/>	Kevin Barry PhD, Public Health Sciences, <i>Member</i>
<input checked="" type="checkbox"/>	<input type="checkbox"/>	Elizabeth Cromwell, PDX Program Lead, <i>Member</i>
<input checked="" type="checkbox"/>	<input type="checkbox"/>	Bernadeta Dadonaitė PhD, Staff Scientist, Basic Sciences, <i>Member</i>
<input checked="" type="checkbox"/>	<input type="checkbox"/>	Neelendu Dey MD, PhD, Clinical Research Division, <i>Member</i>
<input checked="" type="checkbox"/>	<input type="checkbox"/>	Michael Emerman PhD, Human Biology, <i>Member</i>
<input type="checkbox"/>	<input checked="" type="checkbox"/>	Marian Esvelt DVM, Associate Director, Comparative Medicine, <i>Member</i>
<input type="checkbox"/>	<input checked="" type="checkbox"/>	Taran Gujral PhD, Human Biology, <i>Member</i>
<input checked="" type="checkbox"/>	<input type="checkbox"/>	Tony Han, BSL-3/ABSL-3 Facility Manager, <i>Member</i>
<input checked="" type="checkbox"/>	<input type="checkbox"/>	Alex Hirayama MD, Clinical Research Division, <i>Member</i>
<input checked="" type="checkbox"/>	<input type="checkbox"/>	Keith Jerome MD, PhD, Vaccine and Infectious Disease, <i>Chairperson</i>
<input type="checkbox"/>	<input checked="" type="checkbox"/>	Michelle Kom-Gochnour MN, RN, COHN-S, <i>Community Member</i>
<input checked="" type="checkbox"/>	<input type="checkbox"/>	John McNevin MSc, Program Manager, Vaccine and Infectious Disease, <i>Member</i>
<input type="checkbox"/>	<input checked="" type="checkbox"/>	Jacqui Murray-Wijelath PhD, <i>Community Member</i>
<input checked="" type="checkbox"/>	<input type="checkbox"/>	Susan Parazzoli MS, RBP, Biosafety Officer, <i>Member</i>
<input checked="" type="checkbox"/>	<input type="checkbox"/>	Stefan Radtke PhD, Staff Scientist, Translational Science & Therapeutics, <i>Member</i>
<input checked="" type="checkbox"/>	<input type="checkbox"/>	Joshua Schiffer MD, MSc, Clinical Researcher, <i>Member</i>
<input type="checkbox"/>	<input checked="" type="checkbox"/>	Shivani Srivastava PhD, Clinical Research Division, <i>Member</i>
<input checked="" type="checkbox"/>	<input type="checkbox"/>	Susan Strenk, Research Technician IV, Vaccine and Infectious Disease, <i>Member</i>
<input type="checkbox"/>	<input checked="" type="checkbox"/>	Andrea Towleron, HCRI Lab Director, <i>Member</i>
<input type="checkbox"/>	<input checked="" type="checkbox"/>	Allison Zelikoff MN, RN, COHN-S, Occupational Health Manager, <i>Member</i>

NON-MEMBERS

Jake White, Assistant Biosafety Officer, Environmental Health & Safety
 Cindy Wladyka, EH&S Specialist for Biosafety, Environmental Health & Safety

VISITORS

Michelle Choe MD, Study Principal Investigator
 Zoe Worthington PhD, IBC Consultant

Dr. Jerome, Chairperson, called the meeting to order at 2:01 pm.

I. ANNOUNCEMENTS AND UPDATES

- None

II. REMINDER FOR CONFLICT OF INTEREST

The chair reminded the committee that the NIH Guidelines, Section IV-B-2-a-(4) states: "No member of an Institutional Biosafety Committee may be involved (except to provide information requested by the Institutional Biosafety Committee) in the review or approval of a project in which he/she has been or expects to be engaged or has a direct financial interest."

III. MINUTES

None

IV. REVIEW OF ACTION ITEMS

None

V. NEW BUSINESS

HUMAN GENE TRANSFER APPLICATIONS

Principal Investigator:	RG #:	Biosafety Level:	NIH Sections:
Choe	RG1125765	BSL-1	III-C
Summary (including agents, manipulations, genes, hosts, proposed containment/biosafety levels):			
Dr. Choe attended the meeting, gave an overview of the trial and was available for questions from the committee. CAR manufacture is expected to take two weeks after apheresis, followed by participant lymphodepletion and infusion.			
Dr. Choe left the meeting prior to committee discussion and review.			
Committee discussion and review: Standard second generation CAR T study, manufactured here at FH. Phase I open label dose escalation study. Modification by third generation lentiviral vector manufactured at Indiana University Vector Production Facility. FOLR targeting has been used in various contexts without any severe toxicities. No reported cases of RCL in vectors used for modifying T cells.			
Comments & Discussion:			
The Committee reviewed this work and confirmed the research is clearly described, the associated risks recognized, and appropriate biosafety practices implemented in accordance with institutional and regulatory standards.			
Training & Facilities:		Vote & Recusals:	
Facilities have been inspected and are appropriate. Study PI training is up-to-date and complete.		Unanimously approved	

CATEGORY "A" IBC REVIEWS

None

CATEGORY "B" IBC REVIEWS

None

CATEGORY "C" BSO REVIEWS

None

EMUA CLOSEOUTS

None

UPDATES/PROGRAM REVIEW

None

INCIDENTS, ACCIDENTS, AND PROBLEMS

None

VI. OTHER BUSINESS

None

Meeting adjourned at 2:20 pm.

Signed by:



CB83B35EA7A9430

Keith Jerome, MD PhD
Vaccine and Infectious Disease
Institutional Biosafety Committee Chairperson

DocuSigned by:



09CC928C5E494BB

Susan Parazzoli MS, RBP
Biosafety Officer

cc: Dr. Thomas J. Lynch, President, and Director
Dr. Nicole (Niki) Robinson, Chief Administrative Officer